title: Efficacy of rituximab on pulmonary nodulosis occurring or increasing in patients with rheumatoid arthritis during anti-TNF-α therapy.
authors: R
authors: R
authors: De Stefano
authors: E
authors: E
authors: Frati
authors: F
authors: F
authors: Nargi
authors: L
authors: L
authors: Menza
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D057915:Drug Substitution; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D055613:Multiple Pulmonary Nodules / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor; D012218:Rheumatoid Nodule / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D000068879:Adalimumab; D000068800:Etanercept